DaVita Inc. (DVA) shares climbed 24.57%, trading at $138.51, up $27.32, after the kidney-care provider reported strong fourth-quarter and full-year 2025 financial results that surpassed expectations and included robust guidance for 2026.
DaVita posted fourth quarter revenue of $3.62 billion, up nearly 10 percent year-over-year, and adjusted earnings per share of $3.40, beating Wall Street estimates on both top and bottom lines. The company also delivered full-year results with higher earnings and significant cash flow, supported by share repurchases and refinancing actions.
Management's 2026 outlook calls for adjusted earnings well above consensus, reinforcing confidence in continued growth and execution. The company's performance underscored resilience in its core dialysis business, improving revenue per treatment and sustained free cash flow generation, while guidance for 2026 positioned earnings growth ahead of many analyst forecasts.
DVA opened the trading session sharply higher and sustained gains through the day as investors reacted to the earnings beat and upside guidance. Trading volume reflected strong market interest in DaVita's earnings and forward projections.
DaVita's share price has shown volatility over the past year, influenced by earnings cycles, sector dynamics, and investor sentiment around healthcare services, with the latest results driving a significant breakout move.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.